Adebrelimab Plus Carboplatin/Paclitaxel Followed by Adebelizumab with or Without Apatinib in the Treatment of Advanced Recurrent/Metastatic Endometrial Cancer (A-CAPE): a Multicenter, Randomized, Controlled, Open-Label Clinical Trial
Latest Information Update: 20 Jan 2025
Price :
$35 *
At a glance
- Drugs Adebrelimab (Primary) ; Rivoceranib
- Indications Endometrial cancer
- Focus Therapeutic Use
- 20 Jan 2025 New trial record